Epidermal growth factor receptor inhibitors - Revision history

Jensflorian: /* Drugs */ Update

2020-02-13T09:50:44Z

Drugs: Update

← Older revision		Revision as of 09:50, 13 February 2020
Line 10:		Line 10:
	*[[Gefitinib]] (''Iressa'', AstraZeneca).<ref name=pmid20855837/>		*[[Gefitinib]] (''Iressa'', AstraZeneca).<ref name=pmid20855837/>
	*[[Erlotinib]] (''Tarceva'', Roche).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>		*[[Erlotinib]] (''Tarceva'', Roche).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>
	*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>
	Second generation:		Second generation:
	*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>		*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>
	*Afatinib		*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>

	Third generation:		Third generation:
	*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>		*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>

Jensflorian: /* Drugs */ Update

2020-02-13T09:50:00Z

Drugs: Update

← Older revision		Revision as of 09:50, 13 February 2020
Line 13:		Line 13:
	Second generation:		Second generation:
	*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>		*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>
			*Afatinib
	Third generation:		Third generation:
	*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>		*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>
			*Nazartinib

	Note:		Note:
	*Both ''gefitinib'' and ''erlotinib'' are also classified as ''[[tyrosine kinase inhibitors]]'' (TKIs).		*Both ''gefitinib'' and ''erlotinib'' are also classified as ''[[tyrosine kinase inhibitors]]'' (TKIs). After 10-12 months, tumors usu. develop resistencies.

	==Use==		==Use==

Jensflorian: /* Drugs */

2020-02-13T09:43:28Z

Drugs

← Older revision		Revision as of 09:43, 13 February 2020
Line 13:		Line 13:
	Second generation:		Second generation:
	*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>		*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>
			Third generation:
	*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>		*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>

Jensflorian: mutations

2020-02-13T09:41:47Z

mutations

← Older revision		Revision as of 09:41, 13 February 2020
Line 4:		Line 4:
	*EGFR (aka. ErbB1 or HER1) is a membranous receptor expressed in epithelial cells.		*EGFR (aka. ErbB1 or HER1) is a membranous receptor expressed in epithelial cells.
	*Most of activating mutations in [[NSCLC]] are in Exon 18-21 (kinase domain).		*Most of activating mutations in [[NSCLC]] are in Exon 18-21 (kinase domain).
			*45% of the mutations are p.DEL19, approx 40-45% are p.L858R, approx 2% are p.T790M.

	==Drugs==		==Drugs==

Jensflorian: EGFR

2020-02-13T09:38:09Z

EGFR

← Older revision		Revision as of 09:38, 13 February 2020
Line 1:		Line 1:
	'''Epidermal growth factor receptor inhibitors''', abbreviated '''EGFR inhibitors''', is a class of drugs that blocks the EGF receptor.		'''Epidermal growth factor receptor inhibitors''', abbreviated '''EGFR inhibitors''', is a class of drugs that blocks the EGF receptor.

			==EGFR==
			*EGFR (aka. ErbB1 or HER1) is a membranous receptor expressed in epithelial cells.
			*Most of activating mutations in [[NSCLC]] are in Exon 18-21 (kinase domain).

	==Drugs==		==Drugs==

Michael: /* Drugs */

2018-11-08T19:54:34Z

Drugs

← Older revision		Revision as of 19:54, 8 November 2018
Line 3:		Line 3:
	==Drugs==		==Drugs==
	First generation:		First generation:
	*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>		*[[Gefitinib]] (''Iressa'', AstraZeneca).<ref name=pmid20855837/>
	*[[Erlotinib]] (''Tarceva'' Roche).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>		*[[Erlotinib]] (''Tarceva'', Roche).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>
	*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>		*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>
	Second generation:		Second generation:
	*Dacomitinib (''Vizimpro'' Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>		*Dacomitinib (''Vizimpro'', Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>
	*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>		*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>

Michael: /* Drugs */

2018-11-08T19:34:58Z

Drugs

← Older revision		Revision as of 19:34, 8 November 2018
Line 4:		Line 4:
	First generation:		First generation:
	*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>		*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>
	*[[Erlotinib]] (Tarceva).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>		*[[Erlotinib]] (''Tarceva'' Roche).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>
	*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>		*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>
	Second generation:		Second generation:

Michael: /* Drugs */

2018-11-08T19:31:46Z

Drugs

← Older revision		Revision as of 19:31, 8 November 2018
Line 7:		Line 7:
	*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>		*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>
	Second generation:		Second generation:
	*Dacomitinib - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>		*Dacomitinib (''Vizimpro'' Pfizer) - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>
	*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>		*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>

Jensflorian: update

2018-07-16T12:26:32Z

update

← Older revision		Revision as of 12:26, 16 July 2018
Line 2:		Line 2:

	==Drugs==		==Drugs==
			First generation:
	*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>		*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>
	*[[Erlotinib]] (Tarceva).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>		*[[Erlotinib]] (Tarceva).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>
	*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>		*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>
			Second generation:
			*Dacomitinib - not effective when EGFR T790M mutation present.<ref>{{Cite journal \| last1 = Mok \| first1 = TS. \| last2 = Cheng \| first2 = Y. \| last3 = Zhou \| first3 = X. \| last4 = Lee \| first4 = KH. \| last5 = Nakagawa \| first5 = K. \| last6 = Niho \| first6 = S. \| last7 = Lee \| first7 = M. \| last8 = Linke \| first8 = R. \| last9 = Rosell \| first9 = R. \| title = Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. \| journal = J Clin Oncol \| volume = \| issue = \| pages = JCO2018787994 \| month = Jun \| year = 2018 \| doi = 10.1200/JCO.2018.78.7994 \| PMID = 29864379 }}</ref>
			*Osimertinib <ref>{{Cite journal \| last1 = Alsharedi \| first1 = M. \| last2 = Bukamur \| first2 = H. \| last3 = Elhamdani \| first3 = A. \| title = Osimertinib for the treatment of patients with \| journal = Drugs Today (Barc) \| volume = 54 \| issue = 6 \| pages = 369-379 \| month = Jun \| year = 2018 \| doi = 10.1358/dot.2018.54.6.2817668 \| PMID = 29998228 }}</ref>

Jensflorian: /* Drugs */

2018-07-16T12:22:05Z

Drugs

← Older revision		Revision as of 12:22, 16 July 2018
Line 4:		Line 4:
	*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>		*[[Gefitinib]] (Iressa).<ref name=pmid20855837/>
	*[[Erlotinib]] (Tarceva).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>		*[[Erlotinib]] (Tarceva).<ref name=pmid20855837>{{cite journal \|author=Sun Y, Ren Y, Fang Z, ''et al.'' \|title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases \|journal=J. Clin. Oncol. \|volume=28 \|issue=30 \|pages=4616–20 \|year=2010 \|month=October \|pmid=20855837 \|doi=10.1200/JCO.2010.29.6038 \|url=}}</ref>
			*Afatinib (Gilotrif) - esp. effective when del19 is present.<ref>{{Cite journal \| last1 = Yang \| first1 = JC. \| last2 = Wu \| first2 = YL. \| last3 = Schuler \| first3 = M. \| last4 = Sebastian \| first4 = M. \| last5 = Popat \| first5 = S. \| last6 = Yamamoto \| first6 = N. \| last7 = Zhou \| first7 = C. \| last8 = Hu \| first8 = CP. \| last9 = O'Byrne \| first9 = K. \| title = Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. \| journal = Lancet Oncol \| volume = 16 \| issue = 2 \| pages = 141-51 \| month = Feb \| year = 2015 \| doi = 10.1016/S1470-2045(14)71173-8 \| PMID = 25589191 }}</ref>


	Note:		Note: